What is HC Wainwright's Estimate for CRDL FY2028 Earnings?

Key Points

• HC Wainwright raised its FY2028 EPS estimate for Cardiol Therapeutics to $0.45 (from $0.38), maintains a Buy rating with a $9.00 price target, and projects FY2029 EPS of $0.94 and FY2030 EPS of $2.13.
• By contrast, the market consensus for Cardiol's current full-year EPS is ($0.33); the company last reported EPS of ($0.05) (beating estimates of ($0.09)) and the stock trades near $1.41 with a market cap around $158 million.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at HC Wainwright boosted their FY2028 earnings per share estimates for Cardiol Therapeutics in a report issued on Thursday, April 2nd. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.45 for the year, up from their prior estimate of $0.38. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' FY2029 earnings at $0.94 EPS and FY2030 earnings at $2.13 EPS.

Separately, upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cardiol Therapeutics currently has an average rating of "Hold" and an average target price of $9.00.

Cardiol Therapeutics Stock Up 0.7%

CRDL opened at $1.41 on Friday. The stock's fifty day simple moving average is $1.05 and its 200 day simple moving average is $1.05. Cardiol Therapeutics has a 1-year low of $0.77 and a 1-year high of $1.59. The stock has a market cap of $157.66 million, a PE ratio of -5.04 and a beta of 0.81. The company has a current ratio of 3.89, a quick ratio of 3.89 and a debt-to-equity ratio of 0.01.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04.

Hedge Funds Weigh In On Cardiol Therapeutics

Large investors have recently made changes to their positions in the company. Simplex Trading LLC boosted its stake in Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company's stock valued at $31,000 after purchasing an additional 15,842 shares during the period. AdvisorShares Investments LLC increased its position in Cardiol Therapeutics by 7.3% during the 4th quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company's stock worth $570,000 after buying an additional 40,589 shares during the period. Citadel Advisors LLC lifted its holdings in shares of Cardiol Therapeutics by 1,132.6% during the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company's stock worth $496,000 after buying an additional 425,862 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Cardiol Therapeutics by 1,983.0% in the third quarter. Bank of America Corp DE now owns 551,053 shares of the company's stock valued at $590,000 after acquiring an additional 524,598 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Cardiol Therapeutics in the third quarter valued at about $249,000. Institutional investors own 12.49% of the company's stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.